Lilly Endowment Sold Eli Lilly Stock Worth Over $111B in Career Form 4 Value — and December 2025 Was Just the Latest Window
Lilly Endowment, the 10%-plus owner of Eli Lilly, has reported $111B+ in career Form 4 sell transactions. The December 2025 filing continues decades of systematic diversification.
What Happened
Lilly Endowment Inc., the Indianapolis-based private foundation and 10%-plus beneficial owner of Eli Lilly & Co (LLY), filed its latest Form 4 with transactions dated December 29, 2025. Lilly Endowment has been a systematic seller of LLY stock for decades, with career Form 4 filings reporting over $111.8 billion in cumulative sell value across 10,747 transactions.
Why It Matters
Lilly Endowment is one of the largest private foundations in the United States, with assets exceeding $50 billion. The foundation was created by the Lilly family and historically held a concentrated position in Eli Lilly stock. For decades, it has been gradually diversifying — selling LLY shares and redeploying the proceeds into grants and a more diversified investment portfolio.
The selling is not a signal about Eli Lilly’s business prospects. It is mandated by the foundation’s fiduciary duty to diversify and by IRS rules requiring minimum annual distributions. The $111B+ career sell figure reflects the combination of volume (10,747 transactions) and Eli Lilly’s enormous stock price appreciation over decades.
Context
Eli Lilly has been one of the best-performing large-cap pharmaceutical stocks, driven by its GLP-1 weight-loss drug (tirzepatide/Mounjaro) and Alzheimer’s treatment pipeline. The stock traded above $1,000 per share in late 2025. Despite decades of selling, Lilly Endowment remains a significant shareholder due to the stock’s price appreciation outpacing the foundation’s sell rate.
What to Watch
- Lilly Endowment’s quarterly Form 4 filings for continued systematic selling
- Eli Lilly’s GLP-1 market share trajectory and pipeline updates
- Whether the foundation’s LLY concentration continues to decrease or stabilizes
Related Research
Explore all researchThe 220-year-old London-based asset manager's US equity book reveals a distinctly European conviction — GOOGL as the #3 holding at 6.03%, plus aggressive adds in TEVA (+261%), CX (+406%), and new global commodity ETF positions.
Mar 30, 2026
Simplex Trading reported a $177.41B Q4 2025 13F, but the filing reads less like a stock portfolio and more like an options-heavy market-structure book. That distinction is the whole story.
Apr 1, 2026
CalPERS' latest 13F reveals $174.90B in reported AUM with VOO at 11.89% — nearly $20B in one S&P 500 ETF. Combined with NVDA at 8.55%, the top-2 holdings account for 20.44% of this pension giant's portfolio.
Mar 30, 2026
Arrowstreet Capital's systematic models triggered one of Q4 2025's most aggressive Apple trims (-38% shares) while more than doubling Google. With 93 new positions and $170.74B in 13F assets, here's what the quant signals are saying.
Mar 30, 2026
Janus Henderson (WhaleScore 75.50) opened 67 new positions while exiting 67 in Q4 2025 — a 13.4% turnover rate signaling active repositioning. New biotech/med-device bets (ISRG, GPCR, PTGX) hint at a healthcare conviction thesis.
Mar 30, 2026